Target Price Playground
GSK
$47.76
Swing & Horizon Engine
Need pre-expiry P&L (+3d / +5d), multi-leg ratios, or hedged overlays on GSK? Launch with your exact active legs & +12.0% target.
โก Quant Efficiency Alert: Bull Call Spread Delivers
+211.2% ROI
vs
+140.7% ROI
on Long Call at $53.49 Target
Bull Call Spread cuts entry cost by 30% ($161 vs $228), lowers breakeven to $49.61 (+3.9%), and slashes daily theta burn from $2.28/d to $0.67/d.
Forward Projection
If price hits $53 by Jan 15
Multi-Option Simulator
Pre-expiry +3d/+5d & Overlays
Options Architect
Multi-leg solver & Greeks
1x1x1 Structure
Reverse Time-Diagonal + Call
๐ Strategy
Long Stock
Long Call
Long Put
Bull Call Spread
Bear Put Spread
Bear Call Credit Spread
Bull Put Credit Spread
Covered Call
Protective Put
Cash-Secured Put
Diagonal Put Spread
Long Straddle
Bullish. Unlimited upside, capped loss = premium paid.
๐ฏ Target
1-Click Institutional Target Anchors:
56d from today
โ๏ธ Legs
LONG CALL ยท $48 ยท Jan '27
Qty 1 ยท Premium $2.28 ยท ฮ 0.53
P&L at Expiry
Stock (100 sh)
Long Call
Now
Target
๐ก Stock vs Options at Target
If GSK hits $53 by Jan 15: the long call returns +$321 (140.7%) on $228 risked, vs +$573 (12.0%) for 100 shares on $4,776. Options give 11.7ร capital efficiency.
๐ Expiry & Gamma Wall Alignment
Options expire Jan 15, 2027 (56 days out). P&L shown is the value at expiry if GSK is at $53.
๐ Projected Return
P&L if GSK hits $53 by Jan 15
+$321
+140.7% on $228 risked
Max Profit
Unlimited
Unlimited upside
Max Loss
โ$228
Premium paid
Break-even
$50.28
+5.28% from spot
Prob. of Profit at Expiry (PoP)
33.1%
Above breakeven ($50.28)
ยท Touch Target: 31%
30-Day Theta Burn (If Flat)
โ$68
29.8% of entry cost ยท Daily ฮ: $-2.28/day
Net ฮ / ฮ / V
52.98 / -2.28 / 7.44
per spread, per $1 move / day / vol pt
๐ P&L Scenarios โ what happens at different prices and dates
| GSK Price | Today | +3d (Nov 23) | +7d (Nov 27) | Dec 8 | Dec 27 | Jan 15 (exp) |
|---|---|---|---|---|---|---|
| $38 (-20%) | -$222 | -$223 | -$224 | -$227 | -$228 | -$228 |
| $41 (-15%) | -$208 | -$210 | -$213 | -$220 | -$227 | -$228 |
| $43 (-10%) | -$173 | -$177 | -$183 | -$198 | -$220 | -$228 |
| $45 (-5%) | -$106 | -$112 | -$120 | -$144 | -$189 | -$228 |
| $47 (-2%) | -$48 | -$54 | -$63 | -$90 | -$146 | -$228 |
| $48 (0%) โ spot | -$0 | -$7 | -$16 | -$44 | -$104 | -$228 |
| $49 (+2%) | +$54 | +$47 | +$38 | +$9 | -$50 | -$156 |
| $50 (+5%) | +$146 | +$139 | +$130 | +$103 | +$48 | -$13 |
| $53 (+10%) | +$326 | +$320 | +$312 | +$290 | +$251 | +$226 |
| $53 (+12%) โ target | +$405 | +$400 | +$393 | +$373 | +$340 | +$321 |
| $55 (+15%) | +$530 | +$526 | +$520 | +$503 | +$478 | +$464 |
| $57 (+20%) | +$751 | +$748 | +$743 | +$731 | +$715 | +$703 |
Uses GSK's current IV for repricing. P&L includes all legs (stock + options). Qty: 1x.